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Tara M. Mastracci, MD, MSc.(HRM),a Roy K. Greenberg, MD,a Adrian V. Hernandez, MD, PhD,b and
Catherine Morales, BSc,a Cleveland, Ohio
Background: Long-term survival benefit contrasted with rupture risk should determine which patients are suitable for
abdominal aortic aneurysm (AAA) intervention. Our aim was to develop a model capable of predicting long-term survival
based on preoperative characteristics.
Methods: A prospective cohort study using Cox regression modeling. We aimed to associate preoperative characteristics
with long-term mortality, and create a predictive nomogram, which was then externally validated on an independent
cohort (697 patients) who underwent endovascular abdominal aortic aneurysm (AAA) repair.
Results:We pooled the results of 412 patients undergoing endovascular repair of infrarenal and juxtarenal aneurysm who
were high risk (average Glasgow aneurysm scores of 72.8 [SD 10.4]). Despite anatomic differences, there were no
statistically significant differences in perioperative or long-term outcomes between infrarenal and juxtarenal aneurysms
(log rank test, P  .5). Data from this group (64% infrarenal aneurysms and 36% juxtarenal aneurysms) were randomly
and evenly split into a model development and test group. Independent predictors of mortality included in the model are
age, aneurysm diameter, history of peripheral artery disease, chronic obstructive pulmonary disease (COPD), or
congestive heart failure, requirement for supplemental home oxygen, and use of salicylates. Internal validation reveals
good calibration and discriminative ability (c-statistic 0.68 [95% confidence interval 0.65-0.71]). External validation
confirms good calibration.
Conclusions: In the context of acceptable perioperative results, long-term mortality risk can be predicted in endovascular
AAA repair and must be balanced against risk of rupture to determine which patients should be offered treatment.
(J Vasc Surg 2010;51:1088-95.)The rationale for intervention in abdominal aortic an-
eurysm (AAA) is to prevent rupture and prolong survival.
Recently, an interest has begun to relate preoperative vari-
ables with long-term survival in the endovascular popula-
tion.1-3 Periprocedural risk assessment should include the
relative likelihood that aneurysm rupture is the strongest of
all competing factors contributing to late mortality. To
date, there exists no system, developed, and validated in a
population of aneurysm patients, to predict when treat-
ment will prolong longevity. Scoring systems have been
used to predict outcomes in patients with AAA, but most
have focused on perioperative mortality (Table I). Al-
though the discriminative ability for some reports has been
considered “good,” often variables are altered or sample
sizes small, which may challenge the reliability of the orig-
inal model.1,4-6 The known biases imposed on predictive
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1088models by the treatment environment obligate robust ex-
ternal validation to improve generalizability.7
In patients with acceptable operative risks, periproce-
dural benefit for endovascular repair compared with open
surgery has been established by prospective randomized
trial,8,9 prospective multicenter control trials,10-15 other
non-controlled prospective series,16,17 and evidence to
support long-term survival benefit is emerging.3,18 How-
ever, in patients considered high risk or unfit for open
surgery, endovascular intervention may be denied because
of a perceived increased periprocedural risk due to medical
or anatomic complexity, with limited evidence to support
the decision. Minimally invasive endovascular procedures
provide an appealing alternative, yet such a practice contra-
dicts the only randomized controlled trial conducted for
patients with high medical risk, which found no survival
benefit over surveillance (hazard ratio [HR] 1.01, 95%
confidence interval [CI] 0.87-1.69, P  0.25).19 The
subjective grouping of patients into “surgically fit” and
“unfit” categories has created significant debate. Further-
more, no data exist defining the benefit of treatment in
patients with challenging anatomy. Series of conventional
open repair of juxtarenal and perivisceral aneurysms report
higher perioperative morbidity and mortality,20,21 yet sin-
gle center series of endovascular repair report respectable
perioperative and longer-term survival rates.10,22-24
The focus of this research was to develop and validate a
scoring system that would be predictive of long-term sur-
vival following aortic intervention, based upon comorbid
factors, rather than a dichotomous, subjective grouping of
high-risk vs low risk patients. Using a large prospective
database, an analysis was conducted to measure periopera-
tive status and long-term mortality to create a predictive
ication
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validation with a larger group of endovascular patients
derived from a multicenter trial.
METHODS
From September 1998 until December 2005, patients
at a quaternary care center considered high risk for open
abdominal aortic aneurysm (AAA) repair were enrolled into
two investigational device exemption trials. All patients
signed an informed consent approved by our institutional
review board. The studies were prospective, nonrandom-
ized and designed to assess the short- and long-term out-
comes of endovascular AAA repair. Patients were implanted
with a bifurcated Zenith endograft10,24,25 or, in the setting
of short proximal necks, a Zenith Fenestrated endovascular
device26 (Cook Inc, Bloomington, Ind). Temporal enroll-
ment differences were related to device evolution. Demo-
graphic information, preoperative medical risk factors, and
details regarding relevant aortic anatomy were captured.
Follow-up studies included clinical, laboratory, and imag-
ing studies at 1, 6, and 12 months and annually thereafter.
Survival data was supplemented with the Social Security
Death Index quarterly and routine phone calls to families.
Patient selection was guided by inclusion and exclusion
Table I. Development, validation or utilization of predict
Score
Development
population
Modification of
original
model (c-statistic)
Glasgow
aneurysm
score
Elective open AAA52 F
T
B
VBHOM Elective open AAA54 H
T
APACHE-AAA Critical Care55 Open AAA (Hadj
2005 (0.845))5
H
POSSUM All vascular
Surgery56
Open
elective/RAAA57
H
Comorbidity
severity score
Reporting standards Rutherford 199758
Chaikof 200227
F
Leiden score Elective open AAA59 F
Estimation of
physiologic
ability
surgical stress
(E-PASS)
Gastrointestinal
surgery
T
Cleveland
Clinic
experience
Elective EVAR
AAA, Abdominal aortic aneurysm; EVAR, endovascular aneurysm repair.
Development populations are provided for each score in the second colum
noted in the next column. Then perioperative and long-term use is also a
long-term outcomes. Both Baas et al1 and Bianciari et al2 are post hoc applcriteria defined within the study protocols.23,24 Patientswere required to be considered high risk for open repair and
this decision was left to the discretion of the treating
physician. The guidelines provided to implanting physi-
cians cited pulmonary issues (FEV1  1 liter or disabling
chronic obstructive pulmonary disease [COPD]), cardiac
disease (symptomatic coronary artery disease [CAD], base-
line ejection fraction 30%, or positive cardiac functional
studies without good revascularization options), or multi-
ple prior abdominal or aortic procedures as recommenda-
tions for high risk qualification. Smoking status was classi-
fied into three groups (previous smoker, current smoker, or
never smoked). Mortality, morbidity, and post-procedure
imaging studies were evaluated in accordance with themost
recent version of the endovascular reporting standards doc-
ument,22,27 The cause of death was ascertained from state
issued death certificates, hospital expiration summaries,
autopsy results, or family statements. Deaths were catego-
rized as cardiac, pulmonary, cancer, renal, neurologic, an-
eurysm related, or other.
All data captured were entered and stored in a remote
database (Oracle Clinical v 4.03; Redwood Shores, Calif).
Categorical variables were compared using 2 test, and
continuous variables with the t test. Life table analysis and
Kaplan-Meier (K-M) curves were used to evaluate survival.
ores in non-urgent AAA repair
rioperative AAA utilization Long-term AAA utilization
Open
statistic)
Endovascular
(c-statistic)
Open
(c-statistic)
Endovascular
(c-statistic)
2007
2)4
007
4)53
008 (0.79)1
Faizer 2007
(0.47)4
Biancari 2006
(0.7)2
Baas 2008
(0.87)1
Baas 2008
(0.74)1
Biancari 2006 (no
C-estimate)2
Baas 2008 (0.78)1
007
77)49
007
2)53
7(0.842)6,49
007
81)49
2007
4)4
Faizer 2007
(0.69)4
2007
1)4
Faizer 2007
(0.7)4
007
2)53
 this report
he original population was a nonaneurysm population, the modification is
ted. Note that most predictive scores are not validated or used to predict
s of predictive scores.ive sc
Pe
(c-
aizer
(0.7
ang 2
(0.8
aas 2
adj 2
(0.7
ang 2
(0.8
adj
200
adj 2
(0.8
aizer
(0.7
aizer
(0.7
ang 2
(0.9
n. If t
nnotaDifferences in survival between K-M curves were evaluated
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compare patient characteristics with risk of overall death,
for which we used the Cox proportional hazards models,
and obtained HR and 95% CI as measures of association.
Patient characteristics tested were limited to the variables
chosen a priori. Variables were chosen after a review
of the literature was conducted, and included age,4,28-31
sex4,28,30,32 COPD,4,29,31 chronic renal insufficiency (CRI, se-
rum creatinine125 mol/L),4,33 cerebrovascular disease,4,29
congestive heart failure (CHF),4 hypertension,4 and coro-
nary intervention (coronary artery bypass grafting [CABG]
or percutaneous coronary intervention [PCI]).31 We also
chose to include preoperative prescription of common medi-
cations including aspirin, clopidogrel, coumadin, any statin,
and any beta-blocker. Patient’s prescriptions were revised
to best medical management in the postoperative period.
Wherever possible, continuous variables were used. The
assumption of proportionality of hazards was evaluated in
every univariable analysis, and no variable needed to be
transformed to maintain this assumption. All variables with
a P value of.2 in the univariable analysis were included in
themultivariable analysis. Any variable with a P .05 in the
multivariable model was considered statistically significant
and kept in the final model. The performance of the model
was evaluated according to discrimination and calibration.
The measure of discrimination used is the c-statistic that is
similar to the area under a receiver operating calibration
(ROC) curve when using dichotomous outcomes. We used
the calibration plot as a way to show agreement between
predicted and actual mortality risks. Both calibration and
discrimination of the model were internally validated using
the bootstrapping technique (n  200). Thus, a shrinkage
factor was calculated and used to adjust model coefficients
(“shrunk coefficients”) to avoid overfitting when applied to
new populations. All analyses for this study were performed
with S-Plus 7.0 (Insightful Corporation, Seattle, Wash).
We also conducted external validation on our model
using data from a separate endovascular population to
assess discrimination and calibration. The Zenith Multi-
center Trial (ZMT) dataset include all patients (n  697)
treated with a Zenith endovascular infrarenal device in a
trial setting and has two subgroups, 266 high risk patients
and 431 standard risk patients.10 This data was provided by
the sponsoring company, who collected and maintained
the database. The proportion of deaths during a follow-up
of 70 months was 20% overall (172/697), and the propor-
tion of deaths in the same time was about 25% in the high
risk subgroup (66/266). We planned to use the “shrunk”
coefficients from our final Coxmodel and apply them to the
covariables from the ZMT dataset. To further confirm
validity, we also planned a separate analysis using the high
risk and standard risk populations within the ZMT cohort.
RESULTS
A total of 412 patients were enrolled in the trials: 262
patients were repaired with bifurcated devices (high
medical risk [Bifurcated]) and 150 with fenestrated de-
vices (high medical and anatomic risk [Fenestrated]).Data was collected over 11 years (1998-2009) with the
mean follow-up of 48.1 months (standard deviation [SD]
27). The average Glasgow aneurysm score in the cohort
was 72.8 (SD 10.4). Patient characteristics are demon-
strated in Table II and comparison with the validation
cohort is presented in Table III.
Survival. The 30-day mortality for the entire popula-
tion was 1.2% (5/412). There were three perioperative
deaths in the bifurcated group (1.1%) and two in the
fenestrated group (1.3%). Long-term survival is illustrated
in Fig 1. There was no statistically significant difference in
long term outcome between the two groups (log rank test
P  .5).
Patient characteristics associated with mortality.
Risk factors for any mortality in the follow-up period are
presented in Table IV. Variables included in the multivari-
ate analysis were age, male sex, aortic diameter, prior cere-
brovascular disease, prior CHF, prior CAD, prior periph-
eral artery disease, CRI, serum creatinine at baseline,
COPD, use of supplemental O2, history of cancer, use of
aspirin, clopidogrel, warfarin, beta-blockers and statins,
increasing aortic diameter, history of congestive heart fail-
ure, COPD, and use of home oxygen. Independent predic-
tors of death by multivariable analysis are listed in Table V.
Prognostic model. The results of multivariable anal-
ysis were used to create a nomogram for patients undergo-
ing endovascular repair (Fig 2). The model can be used to
estimate mortality at 2 years, 4 years, and 8 years of follow-
up. The model is well calibrated (Fig 3, online only) and
shows good discrimination with a c-statistic of 0.68 (95%
CI 0.65-0.71). The error bars on this figure provide infor-
mation about the precision of estimates. The shrunk coef-
ficient derived after bootstrapping was 0.91, and applica-
tion of it to the original model coefficients did not alter the
strength of discrimination, but improved calibration.
External validation was performed and the discrimina-
tive ability of our model is nearly identical when applied in
the ZMT population (c-statistic 0.69, 95% CI 0.66-0.72),
with no statistically significant difference from the develop-
ment cohort. Analyses were performed by dividing the
ZMT population into subgroups of high risk and standard
risk patients. We calculated c-statistics of 0.63 (95% CI
0.59-0.67) and 0.71 (95% CI 0.66-0.76), respectively.
Calibration of our model on the high risk and the standard
risk subgroups of ZMT patients showed good fit (Fig 4,
online only). This supports the reliability and generalizabil-
ity of the model in the endovascular population.
DISCUSSION
The application of a less invasive aortic intervention for
patients considered poor candidates for open repair is intu-
itive. However, risk assessment focused on periprocedural
events, even in patients who are optimized prior to repair,
may be misdirected in patients with multiple comorbidities
threatening longevity. This series demonstrates that excel-
lent periprocedural mortality (1.2%) can be achieved in
patients with considerable medical risk, which contradicts
the RCT evidence to date19 and allows for a true assessment
JOURNAL OF VASCULAR SURGERY
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qua non of determining operative eligibility, may not be the
most valid method and may be less precise when determin-
ing long-term survival. As the endovascular era evolves, the
question we pose should not be “Will this high risk patient
survive the procedure?” but rather “Will this procedure
Table II. Characteristics of patients included in our datab
bifurcated cohort
Patient characteristic
T
(n 
Age (years; mean, SD) 75.4
Male (n, %) 363
Aortic diameter (mm; mean, SD) 64
Prior cerebrovascular disease (n, %) 69
Prior chronic heart failure (n, %) 87
Prior coronary artery disease (n, %) 240
Prior peripheral artery disease (n, %) 43
Preoperative SBPa (mm Hg; mean, SD) 133.7
Preoperative DBPa (mmHg; mean, SD) 74.2
Chronic renal insufficiency (n, %)b 114
Serum creatinine at baseline (mol/L; mean, SD) 121.9
COPD (n, %) 155
Supplemental home oxygen (n, %) 47
Current smoking (n, %) 72
Diabetes (n, %) 67
History of cancer (n, %) 87
Use of aspirin (n, %) 193
Use of clopidogrel (n, %) 41
Use of warfarin (n, %) 57
Use of beta-blockers (n, %) 159
Use of statins (n, %) 172
COPD, Chronic obstructive pulmonary disease; DBP, diastolic blood pressu
aValues were recorded within 2 days prior to intervention.
bDefined as serum creatinine 125 mol/L.
Table III. Comparison of development and validation
cohorts
Patient characteristic
Development cohort
(CCF Data)
(n  412)
Zenith cohort
(n  as noted)
Age (years; mean, SD) 75.4 (7.5) 73.3 (7.8)
n  740
Male (n, (%)) 363 (88) 680/740 (91.9)
Aortic diameter (mm;
mean, SD) 64 (11.6) 56.7 (9.0)
n  732
Prior cerebrovascular
disease (n, %) 69 (17) 97/732 (13)
Prior chronic heart failure
(n, %) 87 (21) 81/729 (11.1)
Prior peripheral artery
disease (n, %) 43 (10) 143/723 (19.8)
Chronic renal insufficiency
(n, %) 114 (28)a 9/731 (1.2)b
COPD (n, %) 155 (38) 190/734 (25.9)
Diabetes (n, %) 67 (16) 106/737 (14.4)
COPD, Chronic obstructive pulmonary disease.
aDefined as serum creatinine 125 mol/L.
bDefined as “Diagnosis of renal failure”.prolong this patient’s life?”The perception of a “high risk” or “surgically unfit”
patient has grown out of historic reports and is difficult to
define. Procedural risks have been reported in single center
series,34-36 multicenter trials,10,13,25,37-39 prospective ran-
domized trials,8,9 registries,40,41 and population based
studies.42 The preoperative factors that confer procedural
risk may also contribute to long-term mortality, but the
strength of this association has not been previously known.
For example, we have shown that the procedural risk does
not depend on anatomic complexity and medical comor-
ith break down based on inclusion in the fenestrated or
)
Fenestrated
(n 150)
Bifurcated
(n  262) P value
) 75.1 (7.6) 75.5 (7.5) .6
127 (85) 236 (90) .1
6) 65.6 (11.8) 63.2 (11.5) .05
33 (22) 36 (14) .03
25 (17) 62 (24) .09
78 (52) 162 (62) .05
19 (13) 24 (9) .3
4) 134.6 (22.6) 133.2 (20.7) .5
2) 75.7 (11.4) 73.3 (11.1) .04
33 (22) 81 (31) .05
8) 107.3 (35.9) 130.3 (84.9) .002
63 (42) 92 (35) .2
23 (15) 24 (10) .06
30 (21) 42 (17) .3
25 (17) 42 (16) .9
37 (25) 50 (19) .2
80 (53) 113 (43) .05
24 (16) 17 (7) .002
20 (13) 37 (14) .8
57 (38) 102 (39) .9
64 (43) 110 (42) .9
P, systolic blood pressure.
Fig 1. Kaplan Meier curve for survival of patients in the fenes-
trated and bifurcated groups.ase, w
otal
412
(7.5
(88)
(11.
(17)
(21)
(58)
(10)
(21.
(11.
(28)
(71.
(38)
(11)
(19)
(16)
(21)
(47)
(10)
(14)
(39)
(42)
re; SBbidities for patients undergoing open repair,21,31 but the
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survival may be variable with the refinement of endovascu-
lar techniques.28,42 Knowledge of predictors of longevity
will refocus the process of risk assessment and inform the
decision to operate in patients with multiple comorbidities.
Patients with comorbidities considered high risk for
aneurysm repair have been studied, but results are incon-
sistent.10,19,43,44 The EVAR 2 randomized trial included
all patients who were unfit for open repair and randomized
to either surveillance or endovascular repair,19 and the
ZMT10 also included a cohort of patients considered high
risk (“would not likely do well with open surgery”) based
on a list of standardized inclusion criteria. Differences in
Table IV. Univariable analysis of factors contributing to d
Patient characteristic Yes (n
Treatment (n, %)
Bifurcated 176
Fenestrated 66
Age (years; mean, SD) 76.4
Male (n, %) 210
Aortic diameter (mm; mean, SD) 65.1
Prior cerebrovascular disease (n, %) 42
Prior chronic heart failure (n, %) 64
Prior coronary artery disease (n, %) 141
Prior peripheral artery disease (n, %) 26
Preoperative SBPa (mm Hg; mean, SD) 134
Preoperative DBPa (mm Hg; mean, SD) 74
Chronic renal insufficiency (n, %)b 78
Serum creatinine at baseline (mol/L; mean, SD) 127.7
COPD (n, %) 106
Use of oxygen (n, %) 38
Current smoking (n, %) 39
Diabetes (n, %) 38
History of cancer (n, %) 53
Use of aspirin (n, %) 91
Use of clopidogrel (n, %) 15
Use of warfarin (n, %) 44
COPD, Chronic obstructive pulmonary disease; DBP, diastolic blood press
aValues were recorded within 2 days prior to intervention.
bDefined as serum creatinine 125 mol/L.
Table V. Multivariable analysis of all variables considered
statistically significant after univariate analysis
Patient characteristic
Multivariable
HR (95% CI) P value
Age (per 5-year increase) 1.2 (1.1-1.3) .0001
Aortic diameter (per 5 mm increase) 1.1 (1.1-1.2) .0002
Prior chronic heart failure 1.7 (1.2-2.2) .0001
COPD 1.6 (1.2-2.2) .001
Use of oxygen 1.9 (1.3-2.9) .001
Use of aspirin 0.7 (0.5-0.9) .003
CHF, Congestive heart failure; COPD, chronic obstructive pulmonary
disease; PAD, peripheral arterial disease.
Please note that prior CHF and PAD are defined by patient report or if
reported in notes from referring physicians.
Beta-blockers and statins were not significant in the final model.trial design may help reconcile the difference in periproce-dural mortality between EVAR 2 and ZMT (7% and 0.5%),
however, this would not explain the disparity in 2-year
survival, which was 65% in EVAR 2 and 80% in ZMT. To
date, neither these trials, nor large series aggregate data3
define a method for classifying the high risk endovascular
patient, which makes trial results challenging to compare.
The heterogeneity of the populations is apparent when the
survival of patients who cross over to conventional repair is
examined, which draws questions about the validity of a
physicians’ ability to identify “high risk” patients. It seems
unlikely that the preoperative risk factors of the 47 patients
in our cohort
Death
Univariable
HR (95% CI) P value2) No (n  170)
86 (51) 1.0 (0.8-1.4) .9
84 (49)
73.9 (7.6) 1.5 (1.2-1.7) .00001
153 (90) 0.8 (0.5-1.1) .2
) 62.6 (11.1) 1.4 (1.2-1.7) .0001
27 (16) 1.3 (0.9-2.0) .1
23 (14) 1.6 (1.2-2.2) .001
99 (58) 0.8 (0.6-1.1) .1
17 (10) 1.2 (0.8-1.8) .3
) 134 (22.3) 0.9 (0.8-1.1) .4
) 74 (10.8) 0.9 (0.8-1.1) .4
36 (21) 1.4 (1.0-1.8) .02
) 113.5 (57.8) 1.1 (1.0-1.1) .2
49 (29) 1.6 (1.3-2.1) .002
9 (5) 2.4 (1.7-3.4) .0001
33 (21) 1.0 (0.7-1.5) .9
29 (17) 0.8 (0.6-1.2) .3
34 (20) 1.2 (0.9-1.6) .3
102 (60) 0.6 (0.5-0.8) .0003
26 (15) 0.6 (0.4-1.1) .07
13 (8) 1.6 (1.1-2.2) .01
P, systolic blood pressure.
Fig 2. Nomogram, predicting 2-year, 4-year, and 8-year survival
after aneurysm intervention.eath
 24
(73)
(27)
(7.3)
(87)
(11.9
(17)
(26)
(58)
(11)
(20.8
(11.5
(32)
(79.7
(44)
(16)
(17)
(16)
(22)
(38)
(6)
(18)
ure; SBin the EVAR 2 trial who eventually underwent and survived
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ization that their periprocedural risk was converted to that
of a standard risk patient. Although a distinction between
“high risk” and “fitness for surgery” has been made by the
authors of EVAR 2,45 we believe that using objective,
non-modifiable variables when defining risk (ie, history of
chronic heart failure opposed to uncontrolled congestive
heart failure) will provide a more reliable assessment. Fur-
thermore, there must be a distinction made between pro-
cedural and long-term risk when assessments are under-
taken, so that an informed decision can be made regarding
the benefit of surgery to a patients’ longevity. Regardless of
the definition used, it appears that preoperative risk assess-
ment may be more complex than is captured by physician
discretion alone and thus reinforces our interest in creating
a statistically and clinically sound prognostic model.
Statistical models have been made to assess the proba-
bility of survival following open aneurysm repair, but usu-
ally focus on perioperative mortality or are adapted from
scales developed in other populations.5,46-48 Multiple at-
tempts have been made to validate such scoring systems for
use in endovascular patients.2,6,49-51 However, concerns
have been raised about the validity of these systems as they
may not capture the idiosyncrasies of the endovascular
approach. We have devised a new prognostic model that
incorporates a large experience of patients with multiple
comorbidities, but who underwent repair in a center with
expertise using the latest generation of endovascular device,
thus minimizing the contribution of procedural failure
events to survival, and providing an uncontaminated assess-
ment of long-term risk. Our data is unique in that no
scoring system to date has been developed in a cohort of
endovascular patients and validated in another, indepen-
dent population of endovascular patients.
Our results represent a large single center experience of
high risk endovascular repair reported with complex prox-
imal neck anatomy traditionally excluded from similar co-
horts, and our dataset has a 100% follow-up for mortality.
The average aneurysm size (64 mm, SD 11.6) reflects a
much larger index operative threshold than in recent US
prospective series,10-15 and similar to that of the EVAR
trial. Our ability to analyze both bifurcated and fenestrated
groups together has increased the breadth of cohort to
include all AAAs, rather than just those amenable to con-
ventional repair. Furthermore, the low periprocedural mor-
tality allows us to follow long-term outcome as a function
of the natural history of our patients’ comorbidities, with-
out contamination by procedural failures. This cohort may
differ from others in that we routinely have employed a
practice of aggressive treatment of patients’ comorbidities,
including congestive heart failure, statin therapy, and other
means of managing cardiopulmonary risk prior to endovas-
cular repair. This may limit the generalizability to groups
where factors such as uncontrolled congestive heart failure
are prominent, such as the EVAR 2 group, however, the
difference in outcomes compared with EVAR 2 may empha-
size the importance of such an aggressive pre-intervention
approach.There are several limitations to our study. The patients
are not randomized, and our definition of high risk, al-
though supported by objective variables, was determined
by the physicians’ judgment. Furthermore, the patient pop-
ulation at our institution is a unique group because it is a
quaternary care center that receives many subspecialty re-
ferrals. The patient population is possibly more compliant
and invested in their health than the general population.
We believe we have addressed this limitation to some extent
by validating the model using a population from outside of
our health system. Finally, the results that we present are
more likely a measure of efficacy, rather than effectiveness,
of fenestrated and bifurcated endovascular technique in
high risk patients because of the rich institutional experi-
ence that confers the low periprocedural mortality. Al-
though this gives this report limited generalizability, it does
set a benchmark.
CONCLUSION
Despite a perception of higher periprocedural and
long-term risk, analysis of our high risk population proves
that patients with multiple comorbidities and complex
anatomy can be repaired using endovascular techniques
with acceptable outcomes. Prognosis can be predicted pre-
operatively in patients whose comorbidities are aggressively
managed. This information must be used in context with
the risk of rupture, to determine which patients should be
offered invasive treatments.
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